... NAFLD patients. We also measured fatty acid binding protein 2 (FABP2), a putative biomarker of intestinal permeability in patients with liver disease, since pro-inflammatory gut-derived microbial products may induce inflammatory chemokines such as CCL2. Results: Serum CCL2 levels were weakly associated...

... with ascites or higher grade of obesity, limited operator experience, and availability of technology) making other complementary approaches indispensable [6]. Even if imaging techniques can substitute for liver biopsy (gold standard), there is a lack of biomarkers, prompting further structured evaluation...

... is essential to provide patients with a potentially curative treatment. Furthermore, prognostic biomarkers represent a valuable tool to offer patients a tailored therapeutic approach in accordance to their life expectancy. The clinically most established biomarker carbohydrate antigen 19–9 shows only a limited...

... for SB disease. An accurate and inexpensive biomarker would help identify at-risk patients. Aim: To examine the efficacy of faecal calprotectin (FC) and C-reactive protein (CRP) as predictors of SBCE findings in suspected and known CD. Methods: A prospective observational study. Consecutive patients...

... by measuring the dynamic contractility of activated HSC and the consequent changes in portal pressure and blood flow as a responsive physical biomarker. Conclusion: By understanding progressive and resolving liver fibrosis, a series of therapeutic targets have been identified. At the same time, key mediators...

.... Identifying refractory fibrosis and distinguishing the patients who will respond to anti-inflammatory therapy from those who will require surgery are important clinical requirements, and several new technologies in imaging and serum biomarkers are being applied to this problem. Key Messages: Delayed...

... Endomysial antibody Biomarker Intestinal fatty acid-binding protein National Institutes of Health (NIH) 10.13039/100000002 Other serum markers are warranted to prevent the diagnostic biopsies in all children and in adult patients. Research has been underway for many years...

... as biomarkers and therapeutic targets in CRC. They are currently being evaluated as early detection biomarkers and prognostic classifiers. Polymorphisms in miRNAs and miRNA-binding sites may alter one’s risk of CRC. This review will focus on the role of inflammation and miRNAs in colon carcinogenesis...

... involvement of miRNAs in various steps of gastric carcinogenesis: from gastritis toward metastatic disease. Great biological stability of miRNAs opens novel fields in biomarker research with potential clinical implementation in screening, diagnosis, prediction of prognosis and therapeutic management...

... HCC. However, disease stabilization with sorafenib lasts a few months, possibly due to the development of resistance, and thus the survival advantage was modest, even in patients with preserved liver function. Furthermore, there is currently no biomarker for monitoring the response or resistance...